Zhang H, Zhu Y, Yang N, Kong Q, Zheng Y, Lv N
Infect Drug Resist. 2021; 14:4657-4666.
PMID: 34764660
PMC: 8577563.
DOI: 10.2147/IDR.S334200.
Lasarte-Monterrubio C, Vazquez-Ucha J, Maneiro M, Arca-Suarez J, Alonso I, Guijarro-Sanchez P
Antibiotics (Basel). 2021; 10(2).
PMID: 33672671
PMC: 7924334.
DOI: 10.3390/antibiotics10020210.
Lima W, Brito J, da Cruz Nizer W
Med Hypotheses. 2020; 144:110139.
PMID: 32758905
PMC: 7833701.
DOI: 10.1016/j.mehy.2020.110139.
Marques D, Feitosa Machado S, Ebinuma V, de Albuquerque Lima Duarte C, Converti A, Figueiredo Porto A
Antibiotics (Basel). 2018; 7(3).
PMID: 30018235
PMC: 6163296.
DOI: 10.3390/antibiotics7030061.
Wenzler E, Goff D, Humphries R, Goldstein E
Infect Dis Ther. 2017; 6(2):149-172.
PMID: 28260148
PMC: 5446362.
DOI: 10.1007/s40121-017-0149-y.
Task force on management and prevention of Acinetobacter baumannii infections in the ICU.
Garnacho-Montero J, Dimopoulos G, Poulakou G, Akova M, Cisneros J, De Waele J
Intensive Care Med. 2015; 41(12):2057-75.
PMID: 26438224
DOI: 10.1007/s00134-015-4079-4.
Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review.
Izadpanah M, Khalili H
J Res Pharm Pract. 2015; 4(3):105-14.
PMID: 26312249
PMC: 4548428.
DOI: 10.4103/2279-042X.162360.
Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.
Balkan I, Batirel A, Karabay O, Agalar C, Akalin S, Alici O
Indian J Pharmacol. 2015; 47(1):95-100.
PMID: 25821319
PMC: 4375827.
DOI: 10.4103/0253-7613.150383.
Acinetobacter baumannii: A Brief Account of Mechanisms of Multidrug Resistance and Current and Future Therapeutic Management.
Singh H, Thangaraj P, Chakrabarti A
J Clin Diagn Res. 2014; 7(11):2602-5.
PMID: 24392418
PMC: 3879836.
DOI: 10.7860/JCDR/2013/6337.3626.
Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.
Papp-Wallace K, Senkfor B, Gatta J, Chai W, Taracila M, Shanmugasundaram V
Antimicrob Agents Chemother. 2012; 56(11):5687-92.
PMID: 22908165
PMC: 3486531.
DOI: 10.1128/AAC.01027-12.
Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy.
Nottingham M, Bethel C, Pagadala S, Harry E, Pinto A, Lemons Z
Bioorg Med Chem Lett. 2010; 21(1):387-93.
PMID: 21129961
PMC: 3167381.
DOI: 10.1016/j.bmcl.2010.10.134.
Three decades of beta-lactamase inhibitors.
Drawz S, Bonomo R
Clin Microbiol Rev. 2010; 23(1):160-201.
PMID: 20065329
PMC: 2806661.
DOI: 10.1128/CMR.00037-09.
Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India.
Gaur A, Garg A, Prakash P, Anupurba S, Mohapatra T
J Health Popul Nutr. 2008; 26(2):183-8.
PMID: 18686551
PMC: 2740671.
Acinetobacter baumannii: emergence of a successful pathogen.
Peleg A, Seifert H, Paterson D
Clin Microbiol Rev. 2008; 21(3):538-82.
PMID: 18625687
PMC: 2493088.
DOI: 10.1128/CMR.00058-07.
Treatment options for multidrug-resistant Acinetobacter species.
Gilad J, Carmeli Y
Drugs. 2008; 68(2):165-89.
PMID: 18197724
DOI: 10.2165/00003495-200868020-00003.
Ampicillin/sulbactam: current status in severe bacterial infections.
Rafailidis P, Ioannidou E, Falagas M
Drugs. 2007; 67(13):1829-49.
PMID: 17722953
DOI: 10.2165/00003495-200767130-00003.
Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Choi J, Kim C, Park Y, Yoon H, Shin S, Kim Y
Yonsei Med J. 2006; 47(1):63-9.
PMID: 16502486
PMC: 2687582.
DOI: 10.3349/ymj.2006.47.1.63.
Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.
Kollef M
Crit Care. 2005; 9(5):459-64.
PMID: 16277734
PMC: 1297604.
DOI: 10.1186/cc3757.
Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Wood G, Hanes S, Boucher B, Croce M, Fabian T
Intensive Care Med. 2003; 29(11):2072-6.
PMID: 14556048
DOI: 10.1007/s00134-003-1811-2.
Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
Ouderkirk J, Nord J, Turett G, Kislak J
Antimicrob Agents Chemother. 2003; 47(8):2659-62.
PMID: 12878536
PMC: 166058.
DOI: 10.1128/AAC.47.8.2659-2662.2003.